Published in Lancet on August 20, 1994
The α4 nicotinic receptor promotes CD4+ T-cell proliferation and a helper T-cell immune response. Mol Pharmacol (2013) 0.85
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med (1998) 4.65
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Relapses and progression of disability in multiple sclerosis. N Engl J Med (2000) 4.17
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain (1980) 3.27
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol (1988) 2.23
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Multiple sclerosis: a comparison of the latent periods of different populations. Neuroepidemiology (1993) 1.94
Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry (1998) 1.84
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology (2003) 1.73
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol (1997) 1.72
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. J Neurol Sci (2009) 1.52
Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet (1992) 1.50
Neuromyelitis optica and pregnancy. Neurology (2012) 1.49
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler (2007) 1.45
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry (1997) 1.44
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry (2013) 1.42
Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler (2008) 1.41
Clinical parameters to predict response to interferon in relapsing multiple sclerosis. Neuroepidemiology (2008) 1.40
[Familial epilepsy seizure disclosing long QT syndrome]. Rev Neurol (Paris) (1996) 1.39
Variation over time of the effects of prognostic factors in a population-based study of colon cancer: comparison of statistical models. Am J Epidemiol (1999) 1.34
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
[Spontaneous hyperdense intracranial vessels seen on CT scan in polycythemia cases]. J Radiol (2003) 1.30
A regression survival model for testing the proportional hazards hypothesis. Biometrics (1996) 1.27
Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology (2011) 1.23
Ischaemic stroke subtypes and associated risk factors: a French population based study. J Neurol Neurosurg Psychiatry (2008) 1.18
Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler (2009) 1.15
Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler (2009) 1.15
Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine (2008) 1.11
Clinical outcomes assessment in multiple sclerosis. Ann Neurol (1996) 1.11
A semiparametric approach for the two-sample comparison of survival times with long-term survivors. Biometrics (2001) 1.05
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology (2009) 1.05
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology (2012) 1.05
Efficiency of the logistic regression and Cox proportional hazards models in longitudinal studies. Stat Med (1989) 1.04
Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology (1996) 1.03
Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. AJNR Am J Neuroradiol (2012) 1.02
The adolescent and adult form of cobalamin C disease: clinical and molecular spectrum. J Neurol Neurosurg Psychiatry (2008) 1.01
Influence of environmental lead on membrane ion transport in a French urban male population. Environ Res (1990) 1.01
Blood lead concentration and blood pressure. Br Med J (Clin Res Ed) (1985) 1.01
Effects of pregnancy on the inter-individual variations in blood levels of lead, cadmium and mercury. Biol Res Pregnancy Perinatol (1986) 1.00
Diffusion tensor-MRI evidence for extra-axonal neuronal degeneration in caudate and thalamic nuclei of patients with multiple sclerosis. AJNR Am J Neuroradiol (2012) 0.99
Dot-blot immunodetection of antibodies against GM1 and other gangliosides on PVDF-P membranes. J Immunol Methods (1993) 0.97
Environmental exposure to cadmium and human birthweight. Toxicology (1993) 0.97
Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine (2007) 0.97
Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat (1999) 0.94
The combined effect of tobacco and alcohol consumption on the level of lead and cadmium in blood. Sci Total Environ (1985) 0.94
[Causes of paralysis of the hypoglossal nerve. Apropos of 32 cases]. Presse Med (1990) 0.92
[Multiple sclerosis and pregnancy]. Rev Neurol (Paris) (2006) 0.92
Aryl hydrocarbon hydroxylase activity in human placenta of passive smokers. Environ Res (1989) 0.92
Color vision loss among styrene-exposed workers neurotoxicological threshold assessment. Neurotoxicology (1996) 0.91
Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group. Biochim Biophys Acta (1991) 0.91
DNA polymorphism related to HLA-DR2 Dw2 in patients with narcolepsy. Immunogenetics (1985) 0.91
Bone marrow CD34+/B220+ progenitors target the inflamed brain and display in vitro differentiation potential toward microglia. FASEB J (2006) 0.91
New, sensitive fluorogenic substrates for human cathepsin G based on the sequence of serpin-reactive site loops. J Biol Chem (1999) 0.90
Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology (2009) 0.90
Danazol-induced hepatocellular carcinoma. QJM (2003) 0.90
Placental aryl hydrocarbon hydroxylase activity and placental calcifications. Toxicology (1992) 0.90
Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology (2010) 0.90
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol (2012) 0.89
Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler (2007) 0.89
Aryl hydrocarbon hydroxylase activity in human placenta and threatened preterm delivery. J Expo Anal Environ Epidemiol (1993) 0.89
[Estimation of the hazards ratio in two grouped samples]. Biometrics (1985) 0.89
[Association of amyotrophic lateral sclerosis and multiple sclerosis]. Rev Neurol (Paris) (1993) 0.89
[Modelling of length of stay and costs in 2 homogeneous groups of hematological and pneumological patients: clinical characterization of patients with long-stay and high costs]. Rev Epidemiol Sante Publique (1997) 0.88
Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem (2001) 0.88
Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr (2001) 0.88
Prenatal exposure to lead and cadmium and psychomotor development of the child at 6 years. Neurobehav Toxicol Teratol (1986) 0.88
[Anatomo-clinical study of a case of topographic confabulation (or delusion)]. Cortex (1980) 0.88
[Blood lead levels and arterial pressure. Initial results of a cross sectional study of 431 male subjects]. Rev Epidemiol Sante Publique (1982) 0.87
A new, sensitive fluorogenic substrate for papain based on the sequence of the cystatin inhibitory site. Arch Biochem Biophys (1993) 0.87
Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology (2011) 0.87
[Lafora's disease presenting with progressive myoclonus epilepsy]. Rev Neurol (Paris) (2007) 0.86
T-kinin release from T-kininogen by rat-submaxillary-gland endopeptidase K. Eur J Biochem (1988) 0.86
Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler (2013) 0.86
Aneurysmal bone cyst of the cervical spine: report of a case investigated by computed tomographic scanning and treated by a two-stage surgical procedure. Neurosurgery (1982) 0.86
Modeling of high-cost patient distribution within renal failure diagnosis related group. J Clin Epidemiol (1999) 0.86
[Oculo-palatal myoclonus and multiple sclerosis]. Rev Neurol (Paris) (1990) 0.85
[Focal subarachnoid hemorrhage and cerebral amyloid angiopathy: a non-fortuitous association]. Rev Neurol (Paris) (2009) 0.85
High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler (2011) 0.85
[Spatial disorientation. Report of 5 cases (author's transl)]. Rev Neurol (Paris) (1981) 0.85
Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. Neurology (1998) 0.85
Multiple sclerosis and epileptic seizures. Mult Scler (2010) 0.85
National estimate of multiple sclerosis incidence in France (2001-2007). Mult Scler (2012) 0.84
[18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol (2000) 0.84
Dijon's vanishing lead with regard to low incidence of stroke. Eur J Neurol (2009) 0.84
Migraine history and migraine-induced stroke in the Dijon stroke registry. Neuroepidemiology (1999) 0.84
Inhibition of rat tissue kallikrein gene family members by rat kallikrein-binding protein and alpha 1-proteinase inhibitor. FEBS Lett (1992) 0.83
Comparative epidemiology of stroke and acute myocardial infarction: the Dijon Vascular project (Diva). J Neurol Neurosurg Psychiatry (2009) 0.83
Incidence trends of ischemic stroke and transient ischemic attacks in a well-defined French population from 1985 through 1994. Stroke (1999) 0.82
Subsite specificity of trypanosomal cathepsin L-like cysteine proteases. Probing the S2 pocket with phenylalanine-derived amino acids. Eur J Biochem (2001) 0.82
Primary angiitis of the central nervous system: response to mycophenolate mofetil. J Neurol Neurosurg Psychiatry (2009) 0.82
Course of valvular strands in patients with stroke: cooperative study with transesophageal echocardiography. Am Heart J (1998) 0.82